A new breakthrough treatment for advanced bladder cancer has just received FDA approval under the accelerated approval program. The new treatment is Genentech's new cancer immunotherapy medicine TECENTRIQ (atezolizumab). This is the first cancer immunotherapy approved to treat this form of cancer. And until now, there have been no treatment advances for advanced bladder cancer in more than 30 years.
Join us as we talk to Dr. Daniel P. Petrylak, medical oncologist and Professor of Medicine and Urology at the Yale Cancer Center and one of the lead investigators on the TECENTRIQ (atezolizumab) clinical trial, and Lou, a patient from the clinical trial, about the new breakthrough treatment.